Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267830 | 0.88 | ALDH1A1 (0.43) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL28517912 | 0.87 | FBP1 (0.43) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL20267535 | 0.85 | TSHR (0.46) | CYP1A2MAPTALDH1A1CYP2C19TSHR | |
| SCHEMBL11921719 | 0.84 | CYP1A2 (0.53) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL160214 | 0.84 | CYP1A2 (0.53) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL31412793 | 0.84 | CYP1A2 (0.53) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL24499444 | 0.82 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL9714181 | 0.82 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL559854 | 0.82 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL1931216 | 0.82 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| CN-118684633-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113195441-B | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240182462-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11926622-B2 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230212159-A1 | Process for the Production of Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2023-07-06 | — | — | US | disclosed |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | TENAYA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | TENAYA THERAPEUTICS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-12-01 | — | — | US | disclosed |
| EP-4076448-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | Tenaya Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-0964860-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0539421-B1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1998-09-23 | — | — | EP | disclosed |
| WO-1998038173-A1 | ATROPISOMERS OF 3-ARYL-4(3H)-QUINAZOLINONES AND THEIR USE AS AMPA-RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998038187-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| US-5278165-A | Oxazolyl imidazol[4,5-b]pyridin and pyrimidine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-11 | — | — | US | disclosed |
| US-5217980-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-06-08 | — | — | US | disclosed |
| WO-1992001687-A1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-02-06 | — | — | WO | disclosed |
| EP-0154132-B1 | 6-ALKYLIDENE PENEMS, THEIR PREPARATION AND USE, AND INTERMEDIATES | BEECHAM GROUP PLC (GB) | 1992-01-08 | — | — | EP | disclosed |
| US-4798828-A | LACTAMASE INHIBITORS | BEECHAM GROUP P.L.C. (GB) | 1989-01-17 | — | — | US | disclosed |
| EP-0154132-A1 | 6-Alkylidene penems, their preparation and use, and intermediates | BEECHAM GROUP PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212159-A1 | Process for the Production of Ferroportin Inhibitors | HAMP, SLC40A1, FECH | CYP1A2 678/4885NLRP3 3795/4885MAPT 4393/4885 |
| US-11926622-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | CYP1A2 2523/4885NLRP3 3876/4885MAPT 581/4885 |
| US-20240182462-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | HDAC6, HDAC1, HDAC3 | CYP1A2 2523/4885NLRP3 3876/4885MAPT 581/4885 |
| US-12312345-B2 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | CYP1A2 2523/4885NLRP3 3876/4885MAPT 581/4885 |
| US-11578066-B1 | Fluoroalkyl-oxadiazoles and uses thereof | HDAC6, HDAC1, HDAC3 | CYP1A2 2523/4885NLRP3 3876/4885MAPT 581/4885 |
| US-20230143804-A1 | FLUOROALKYL-OXADIAZOLES AND USES THEREOF | HDAC6, HDAC1, HDAC3 | CYP1A2 2892/4885NLRP3 3293/4885MAPT 767/4885 |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | CYP1A2 255/4885NLRP3 4870/4885MAPT 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.